News

Gilead Sciences has set the price of its investigational Covid-19 drug remdesivir at $390 per vial for the US and governments of other developed countries. Current treatment patterns reveal that most patients may require a five-day treatment course, which involves...

AstraZeneca announced that selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and debilitating genetic disease. Selumetinib is co-developed and co-commercialised with MSD Inc., Kenilworth, N.J., US (MSD: known...

Italy-based Stevanato Group, a leading producer of pharmaceutical glass containers and integrated provider of drug delivery systems, continued its growth in 2019, recording a positive trend on key financial indicators. Indeed, the Group's consolidated revenues reached € 570.3 million, an...

Japanese pharmaceutical giant Takeda Pharmaceutical has entered into a research collaboration agreement with US-based Carmine Therapeutics for the discovery, development and commercialisation of rare disease therapies. The partners intend to leverage Carmine’s REGENT technology, based on red blood cell extracellular...

Global biotherapeutics leader CSL Behring announced that it has agreed to acquire exclusive global license rights to commercialize an adeno-associated virus (AAV) gene therapy program, AMT-061 (etranacogene dezaparvovec), for the treatment of hemophilia B from uniQure, a leading gene...

LabCorp, a leading global life sciences company that is deeply integrated in guiding patient care, announced that Covance, its drug development business, has deployed the Xcellerate® COVID-19 solution as part of its award-winning Xcellerate platform. Covance has developed a...

Scientists from UK-headquartered AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyze the genomes of 929 patients from the UK Biobank who...